This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Dombret Hervé, Claude Gardin. An update of current treatments for adult acute myeloid leukemia. Blood 2016;127:53–62.
Jacoby E, Shahani SA, Shah NN. Updates on CAR T-cell therapy in B-cell malignancies. Immunol Rev 2019;290:39–59.
Tasian SK. Acute myeloid leukemia chimeric antigen receptor T-cell immunotherapy: how far up the road have we traveled? Ther Adv Hematol. 2018;9:135–48. https://doi.org/10.1177/2040620718774268.
Kita K, Nakase K, Miwa H, Masuya M, Nishii K, Morita N, et al. Phenotypical characteristics of acute myelocytic leukemia associated with the t(8;21)(q22;q22) chromosomal abnormality: frequent expression of immature B-cell antigen CD19 together with stem cell antigen CD34. Blood. 1992;80:470–7
Ma G, Wang Y, Ahmed T, Zaslav AL, Hogan L, Avila C, et al. Anti-CD19 chimeric antigen receptor targeting of CD19+ acute myeloid leukemia. Leuk Res Rep 2018;9:42–4.
Jacoby E, Bielorai B, Avigdor A, Itzhaki O, Hutt D, Nussboim V, et al. Locally produced CD19 CAR T cells leading to clinical remissions in medullary and extramedullary relapsed acute lymphoblastic leukemia. Am J Hematol. 2018;93:1485–92.
Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transpl. 2019;25:625–38.
Jacoby E, Yang Y, Qin H, Chien CD, Kochenderfer JN, Fry TJ. Murine allogeneic CD19 CAR T-cells harbor potent anti-leukemic activity but have the potential to mediate lethal GVHD. Blood 2016;127:1361–70.
Ghosh A, Smith M, James SE, Davila ML, Velardi E, Argyropoulos KV, et al. Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity. Nat Med 2017;23:242–9.
Cordeiro A, Bezerra ED, Hirayama AV, Hill JA, Wu V, Voutsinas J, et al. Late events after treatment with CD19-targeted chimeric antigen receptor modified T-cells. Biol Blood Marrow Transplant. 2020;26:26–33. https://doi.org/10.1016/j.bbmt.2019.08.003.
Perna F, Berman SH, Soni RK, Hendrickson RC, Brennan CW, Sadelain M. Integrating proteomics and transcriptomics for systematic combinatorial chimeric antigen receptor therapy of AML article integrating proteomics and transcriptomics for systematic combinatorial chimeric antigen receptor therapy of AML. Cancer Cell 2017;32:506–19.e5.
Kim MY, Yu KR, Kenderian SS, Ruella M, Chen S, Shin TH, et al. Genetic inactivation of CD33 in hematopoietic stem cells to enable CAR T cell immunotherapy for acute myeloid leukemia. Cell 2018;173:1439–53.e19.
Cohen AD, Ayers EC, Kerr NDS, Wang Q, Melenhorst JJ, Hwang W-T, et al. Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. JCI Insight. 2018;3.pii: 120505. https://doi.org/10.1172/jci.insight.120505.
Nerreter T, Letschert S, Götz R, Doose S, Danhof S, Einsele H, et al. Super-resolution microscopy reveals ultra-low CD19 expression on myeloma cells that triggers elimination by CD19 CAR-T. Nat Commun 2019;10:3137.
Svoboda J, Rheingold SR, Gill SI, Grupp SA, Lacey SF, Kulikovskaya I, et al. Non-viral RNA chimeric antigen receptor modified T cells in patients with Hodgkin lymphoma. Blood. 2018;132:blood-2018-03-837609.
Author information
Authors and Affiliations
Contributions
Data collection: ID, EJ, MJB, HV, VM-M, AA, and AN; Patient care: ID, RY, NS-T, AS, AA, AN. Analysis and interpretation of data: ID, EJ, HV, VM-M, AA, and AN. Drafting the manuscript: ID, EJ, and AN. All authors approved the manuscript.
Corresponding author
Ethics declarations
Conflict of interest
EJ received honoraria in from Novartis. All other authors report no conflict of interest.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Danylesko, I., Jacoby, E., Yerushalmi, R. et al. Remission of acute myeloid leukemia with t(8;21) following CD19 CAR T-cells. Leukemia 34, 1939–1942 (2020). https://doi.org/10.1038/s41375-020-0719-y
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41375-020-0719-y
This article is cited by
-
RUNX1 mutations in blast-phase chronic myeloid leukemia associate with distinct phenotypes, transcriptional profiles, and drug responses
Leukemia (2021)
-
CAR-T Cell Therapy for Acute Myeloid Leukemia: Preclinical Rationale, Current Clinical Progress, and Barriers to Success
BioDrugs (2021)
-
Anti-cd19-car-transduced-t-cells
Reactions Weekly (2020)